ESMO 2019 | Improving patient selection for surgical candidates with head and neck cancer

Hisham Mehanna • 28 Sep 2019

Head and Neck Cancer

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, FRCS(ORL-HNS), University of Birmingham, Birmingham, UK, discusses improving patient selection for surgical candidates with head and neck cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Evaluating options for HPV+ oropharyngeal cancer: cisplatin-RT vs. cetuximab-RT

Hisham Mehanna • 29 Nov 2018

Updates on HPV+ oropharyngeal cancer - de-escalation and reducing costs with cisplatin

Hisham Mehanna • 30 Sep 2019

Cetuximab for oropharyngeal cancer: latest data from De-ESCALaTE

Hisham Mehanna • 22 Oct 2018

The omega score: an emerging biomarker for risk determination

Hisham Mehanna • 29 Nov 2018

Related Videos

KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC

Barbara Burtness • 9 Nov 2018

Durvalumab plus danvatirsen for R/M HNSCC: exciting SCORES data

Ezra Cohen • 22 Oct 2018

The risks of radioactive iodine treatment in thyroid cancer

Remco Molenaar • 25 Sep 2017

Checkpoint inhibitors for head and neck cancer in the definitive setting?

Barbara Burtness • 9 Nov 2018